Dr. Joel Douglas Mermis, MD

Dr. Mermis practices at The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System.

Dr. Mermis' NPI, 1396814430, was assigned on November 6, 2006. Dr. Mermis graduated from University of Kansas School of Med (KC/Wich/Sal) in 2003. Dr. Mermis holds Kansas license 0432603.

Dr. Mermis' primary practice is The University of Kansas Hospital, at 4000 Cambridge Street, Kansas City, KS 66160 in Wyandotte County. The practice phone is (913) 588-5000.

Dr. Mermis' primary practice is The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System. The medical group on file is Kansas University Physicians. Dmand AI also links Dr. Mermis to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mermis practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Mermis' primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Mermis is licensed in Kansas.

CMS data shows 711 Medicare services from Dr. Mermis across 12 procedure codes in 2024, for 335 Medicare patients. Medicare paid $38,953 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 335 Medicare patients who saw Dr. Mermis in 2024. The largest group is 65 to 74, with 153 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mermis' median patient age at 71, with 54% women.

In 2024, Dr. Mermis wrote 790 Medicare Part D claims for 98 patients. 34% of them were for generic drugs. CMS names the drug for 626 of them, across 18 drugs with 11 or more claims each, at $3,514,728 in total drug cost. In 2023, CMS named 652 claims across 19 drugs.

Dr. Mermis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mermis as offering telehealth.

Dmand AI links 17 papers to Dr. Mermis, published from 2011 to 2025. 2013 was the busiest year, with 2. The most frequent topics are Cystic Fibrosis, Hospital Mortality and Hydroxymethylglutaryl-CoA Reductase Inhibitors. Dr. Mermis has published most often in Chest. Dr. Mermis' most frequent co-authors are Deepika Polineni, MD, Elliott Chandler Dasenbrook, MD and Emily Ann Dimango, MD.

Dmand AI links Dr. Mermis to 4 clinical trials. Conditions studied include Cystic Fibrosis and Infant, Newborn, Diseases.

CMS Open Payments shows 12 general payments to Dr. Mermis from 6 drug and device companies from 2016 to 2019. Food and beverage make up the largest share, 74% of the total. Gilead Sciences, Inc. paid the most, $252.

Dr. Mermis graduated from University of Kansas School of Med (KC/Wich/Sal) in 2003.